Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C514S274000, C544S315000, C544S319000, C544S334000, C544S335000
Reexamination Certificate
active
07317014
ABSTRACT:
The present invention relates to novel derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrimidine derivatives of the general formula (I)
REFERENCES:
patent: 2602794 (1952-07-01), Hitchings et al.
patent: 3772288 (1973-11-01), Hardtmann et al.
patent: 4438117 (1984-03-01), Cherkofsky
patent: 4771040 (1988-09-01), Maurer et al.
patent: 5118686 (1992-06-01), Coates et al.
patent: 5580985 (1996-12-01), Lee et al.
patent: 6410729 (2002-06-01), Spohr et al.
patent: 6420385 (2002-07-01), Spohr et al.
patent: 6867205 (2005-03-01), Boehringer et al.
patent: 2003/0225075 (2003-12-01), Agarwal et al.
patent: 2142317 (1973-03-01), None
patent: 130046 (1985-01-01), None
patent: WO 92/02513 (1992-02-01), None
Douglas, Jr. Introduction to viral diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15) May 1999.
Freston, PubMed Abstract (Am J Med 107(6A):78S-88S; discussions) Dec. 1999.
Naesdal et al., PubMed Abstract (Eur J Gastroenterol Hepatol. 13(12):1401-6) Dec. 2001.
Vippagunta et al., Cyrstalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Ulrich, Chapter 4: Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002.
Hannah et al., CAPLUS Abstract 133:105004, 2000.
Koyama et al., CAPLUS Abstract 78:4210, 1973.
Koyama et al., CAPLUS Abstract 72:90403, 1970.
Chase et al., CAPLUS Abstract 49:36033, 1955.
Tagawa, PubMed Abstract (Curr Pharm Des. 6(6):681-99), Apr. 2000.
Cutting Edge Reportsavailable at http://www.rheuma21st.com/archives/winter—symposium.html, Feb. 23, 2000.
Garderova, et al., “The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents,”Current Drug Targets, vol. 1, pp. 327-364, 2000.
Israel, A., “The IKK Complex: an integrator of all signals that activate NF-κB,” Trends Cell Biol., vol. 10, pp. 129-133 (2000).
Liou, et al., “Regulation of the NF-κB/rel transcription factor and IκB inhibitor system,” Current Opinion in Cell Biology, vol. 5, pp. 477-487, 1993.
Israel, A., “A role for phosphorylation and degradation in the control of NF-κB,” Trends Cell Biol., vol. 11, No. 6, pp. 203-205, 1995.
Gilmore, et al., “The I κB proteins:members of a multifunctional family,” Trends Genet., vol. 9, No. 12, pp. 427-433, 1993.
Anderson, “Toll signaling pathways in the innate immune response,” Curr. Opin. Immunol. vol. 12, pp. 13-19, 2000.
Sen, et al., “Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences,” Cell, vol. 46, pp. 705-716, 1986.
Zhang, et al., “Toll-like receptor-mediated NF-B activation: a phylogenetically conserved paradigm in innate immunity,” Clin. Invest., vol. 107, pp. 13-19, 2001.
Scheinmann, et al., “Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids,” Science, vol. 270, pp. 28386, 1995.
Davis, et al., “Rel-Associated pp. 40: An Inhibitor of the Rel Family of Transcription Factors,” Science, vol. 253, pp. 1268-1271, 1991.
Demarachi, et al., “Activation of Transcription Factor NF-κB by the Tat Protein of Human Immunodeficiency Virus Type 1,” J. Virol., vol. 7, pp. 4427-4437, 1996.
Sha, et al., “Targeted Disruption of the p50 Subunit of NF-κB Leads to Multifocal Defects in Immune Responses,” Cell, vol. 80, pp. 321-330, 1995.
Beg, et al, “Embryonic lethality and liver degeneration in mice lacking the RelA components of NF-κB,” Nature, vol. 376, pp. 167-170, 1995.
Weih, et al., “Multiorgan Inflammation and Hematopoietic Abnormalities in Mice with a Targeted Disruption of RelB, a Member of the NF-κB/Rel Family,” Cell, vol. 80, pp. 331-340, 1995.
Burkly, et al., “Expression of relB is required for the development of thymic medulla and dendritic cells,” Nature, vol. 373, pp. 531-536, 1995.
Tak, et al., “NF-κB: a key role in inflammatory diseases,” J. Clin. Invest., vol. 107, pp. 7-11, 2001.
Yamamoto, et al., “Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer,” J. Clin. Invest. , vol. 107, pp. 135-142, 2001.
Pahl, “Activators and target genes of Rel/NF-κB transcription factors,” Oncogene, vol. 18, pp. 6853-6866, 1999.
Nguyen, et al, “Chemogenomic identification of Ref-1/Ap-1 as a therapeutic target for asthma,” PNAS, vol. 100, No. 3, pp. 1169-1173, 2003.
Grootendorst, et al., “Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD),” Pulmonary Pharmacology and Therapeutics, vol. 16, pp. 341-347, 2003.
Rabinowitz, et al., “Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE),” J.Med.Chem, vol. 44, pp. 4252-4267, 2001.
van den Brink, et al., “Expression and Activation of NF-κB in the Antrum of the Human Stomach,” J.Immunol., vol. 164. pp. 3353-3359, 2000.
Schreiber, et al., “Activation of nuclear factor κB in inflammatory bowel disease,” Gut, vol. 42, pp. 477-484, 1998.
Jobin, et al., “The IκB/NF-κB system: a key determinant of mucosal inflammation and protection,” Am.J. Physiol.Cell Phsiol., vol. 278, C451-C462, 2000 (review).
Tak, et al., “NF-κB: a key role in inflammatory disease,” The Journal of Clinical. Investigation, vol. 107, No. 1, pp. 7-11 2001.
van Heel, et al., “Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors,” Human Molecular Genetics, vol. 11, No. 11, pp. 1281-1289, 2002.
Farrel, et al., “Mechanisms of Steroid Action and Resistance in Inflammation,” Journal of Endocrinology, Vo. 178, pp. 339-346, 2003.
Brand, et al., “Activated Transcription Factor Nuclear Factor-Kappa B is Present in the Aterosclerotic Lesion,” J. Clin. Invest., vol. 97, pp. 1715-1722, 1996.
Wilson, et al., “Activated nuclear factor-κB is present in the coronary vasculature in experimental hypercholesterolemia,” Atherosclerosis, vol. 148, pp. 23-30, 2000.
Cheng, et al., “NF-κB Subunit-specific Regulation of the IκBα Promoter,” J. Biol. Chem., vol. 296, pp. 13351-13557, 1994.
Bowie, et al., “Lipid Peroxidation Is Involved in the Activation of NF-κB by Tumor Necrosis Factor by Not Interleukin-1 in the Human Endothelial Cell Lin ACV304,” J. Biol. Chem., vol. 272, pp. 25941-25950, 1997.
Ozaki, et al., “Overexpression of redox factor-1 protects against postischemic liver injury by reducing oxidative stress and NF-κB,” Transplant, vol. 34, No. 7, pp. 2640-2642, 2002 (Abstract only).
Meister, “Glutathione-Ascorbic Acid Antioxidant System in Animals,” J. Biol. Chem., vol. 269, pp. 9397-9400, 1994.
Hagen, et al., “Bioavailability of dietary glutatione: effect on plasma concentration,” Am. J. Physiol., vol. 259, pp. 524-529, 1990.
Cho, et al., “Glutatione Downregulates the Phosphorylation of IκB: Autoloop Regulation of the NF-κB-Mediated Expression of NF-κB Subunits by TNF-α in Mouse Vascular Endothelial Cells,” Biochem. Biophys. Res. Commun., vol. 253,
Agarwal Shiv Kumar
Aggarwal Pawan
Shivakumar Savithiri
Tadiparthi Ravikumar
Bexel Pharmaceuticals Inc.
Oliff & Berridge PLC.
Orchid Research Laboratories, Ltd.
Rao Deepak
LandOfFree
Bio-active pyrimidine molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bio-active pyrimidine molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bio-active pyrimidine molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806858